ESMO 2021 breast cancer highlights: TULIP and KEYNOTE-355

Highlights in breast cancer from ESMO 2021Подробнее

ESMO Breast 2021 highlightsПодробнее

KEYNOTE-355: First-line pembrolizumab plus chemotherapy for metastatic triple-negative breast ca...Подробнее

Breast cancer trial updates at ESMO 2021Подробнее

ESMO Breast 2021 highlights: biomarker updatesПодробнее

Breast cancer roundup from ESMO 2021Подробнее

Highlights from SABCS 2021: T-DXd, KEYNOTE-355, PADA-1 & EMERALDПодробнее

#ESMO21 Highlights on combination of pembrolizumab plus chemotherapy in mTNBC: The KEYNOTE-355 studyПодробнее

Highlights from ESMO Breast 2021Подробнее

Highlights from ESMO Breast 2021Подробнее

ESMO 2021: key trials for breast cancerПодробнее

GS1-01: "Phase 3 study of pembrolizumab + chemotherapy vs placebo + chemotherapy as neoadjuvant..."Подробнее

ESMO 2020 Expert Video Report on CDK4 6i in the adjuvant treatment of breast cancerПодробнее

Highlights from ESMO: DESTINY-Breast03Подробнее

ESMO 2021 RoundupПодробнее

Breast cancer research at ESMO 2021Подробнее

ESMO Breast 2021: What to expect?Подробнее

Highlights in breast cancer at ESMO 2024: KEYNOTE-522Подробнее